MBA CMA - Pulmatrix Interim Officer
| PULM Stock | USD 6.64 0.70 9.54% |
Insider
MBA CMA is Interim Officer of Pulmatrix
| Age | 69 |
| Address | 36 Crosby Drive, Bedford, MA, United States, 01730 |
| Phone | 781 357 2333 |
| Web | https://www.pulmatrix.com |
Pulmatrix Management Efficiency
The company has return on total asset (ROA) of (0.2999) % which means that it has lost $0.2999 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5899) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Pulmatrix's Non Currrent Assets Other are very stable compared to the past year. As of the 30th of November 2024, Total Current Assets is likely to grow to about 22.2 M, while Non Current Assets Total are likely to drop about 8.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Hoyoung MD | CytomX Therapeutics | 55 | |
| FACP MD | Moleculin Biotech | 70 | |
| Torsten Hombeck | Akari Therapeutics PLC | 54 | |
| Alan MacKenzie | Bio Path Holdings | N/A | |
| Jacqueline Northcut | Moleculin Biotech | 62 | |
| Peter MBA | Bio Path Holdings | 75 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Uri MD | Assembly Biosciences | 52 | |
| James MacKaness | Soleno Therapeutics | 60 | |
| Timothy Moore | Instil Bio | 63 | |
| Donald Picker | Moleculin Biotech | 78 | |
| Linda Marbn | Capricor Therapeutics | 61 | |
| Mark Dudley | Instil Bio | N/A | |
| AO FRACP | Assembly Biosciences | 65 | |
| Eduardo Marbn | Capricor Therapeutics | N/A | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| FMEDSCI MD | Achilles Therapeutics PLC | 49 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.3 |
Pulmatrix Leadership Team
Elected by the shareholders, the Pulmatrix's board of directors comprises two types of representatives: Pulmatrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulmatrix. The board's role is to monitor Pulmatrix's management team and ensure that shareholders' interests are well served. Pulmatrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulmatrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, Interim Officer | ||
| Alexander Klibanov, Founder | ||
| Margaret MD, Chief Officer | ||
| David JD, Advisor | ||
| Aidan Curran, VP Affairs | ||
| Teofilo MBA, CEO President |
Pulmatrix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulmatrix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (3.80) % | ||||
| Current Valuation | 13.47 M | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Institutions | 7.16 % | ||||
| Number Of Shares Shorted | 411.61 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 2.22 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.